Уважаемые коллеги, доброго времени суток! Представляем вам немецкое научное издание Supportive Care in Cancer. Журнал имеет второй квартиль, издаётся в Springer Verlag, его SJR за 2021 г. равен 0,949, пятилетний импакт-фактор 3,677, печатный ISSN - 0941-4355, электронный - 1433-7339, предметная область Онкология. Вот так выглядит обложка:
Редактором является Фредерик Ашбури, контактные данные - fashbury@intel-icon.com.
Дополнительные публикационные контакты - geziele.red@springernature.com, Annalyn.Marabillo@springer.com, journalpermissions@springernature.com, ben.bishop@springer.com.
Журнал предоставляет членам Международной ассоциации поддерживающей терапии при раке (MASCC) и всем другим заинтересованным лицам, группам и учреждениям новейшую научную и социальную информацию по всем аспектам поддерживающей терапии у онкологических больных. Он охватывает в основном медицинские, технические и хирургические темы, касающиеся поддерживающей терапии и ухода, которые могут дополнять или заменять основное лечение рака на всех стадиях заболевания. Сюда также включены вопросы сестринского ухода, реабилитации, психосоциальной и духовной поддержки.
Адрес издания - https://www.springer.com/journal/520
Пример статьи, название - ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancer. Заголовок (Abstract)
Purpose
All patients living with cancer, including those with metastatic cancer, are encouraged to be physically active. This paper examines the secondary endpoints of an aerobic exercise intervention for men with metastatic prostate cancer.
Methods
ExPeCT (Exercise, Prostate Cancer and Circulating Tumour Cells), was a multi-centre randomised control trial with a 6-month aerobic exercise intervention arm or a standard care control arm. Exercise adherence data was collected via heart rate monitors. Quality of life (FACT-P) and physical activity (self-administered questionnaire) assessments were completed at baseline, at 3 months and at 6 months.
Results
A total of 61 patients were included (69.4 ± 7.3 yr, body mass index 29.2 ± 5.8 kg/m2). The median time since diagnosis was 34 months (IQR 7–54). A total of 35 (55%) of participants had > 1 region affected by metastatic disease. No adverse events were reported by participants. There was no effect of exercise on quality of life (Cohen’s d = − 0.082). Overall adherence to the supervised sessions was 83% (329 out of 396 possible sessions attended by participants). Overall adherence to the non-supervised home exercise sessions was 72% (months 1–3) and 67% (months 3–6). Modelling results for overall physical activity scores showed no significant main effect for the group (p-value = 0.25) or for time (p-value = 0.24).
Conclusion
In a group of patients with a high burden of metastatic prostate cancer, a 6-month aerobic exercise intervention did not lead to change in quality of life. Further exercise studies examining the role of exercise for people living with metastatic prostate cancer are needed.
Trial Registration
The trial was registered at clinicaltrials.gov (NCT02453139) on May 25th 2015.